ACE and hypertensive disorder: A clinical trial based on patients with mild to moderate hypertension also discovered that the administration of Benifuuki, whose active ingredient is an EGCG-O-methylated derivative, exerts a hypotensive effect by significantly inhibiting angiotensin I-converting enzyme activity85.